Higher Drug Prices Can Lower Use of Recommended Therapies
Investigators looked at the association of antiparasitic drug prices with prescribing and prescription-filling behaviors and total outpatient treatment costs.
Price increases of drugs used to treat parasitic infections were associated with lower use of recommended treatments, according to a recent study in JAMA Network Open.
The mean wholesale prices of the antiparasitic drugs recommended by the Centers for Disease Control and Prevention to be the standard of care for treating hookworm have increased significantly over the last decade. Investigators in the JAMA study found that the price of Albenza (albendazole) 400 mg increased from $3.16 in 2010 and $582 in 2019, and the price of Emverm (mebendazole) 600 mg increased from $32 in 2010 to $2,853 in 2019.
At the same time, the use of these drug decreased from 43% to 28% of patients for hookworm and from 81% to 28% of patients for pinworm.
The low use of Emverm was associated with its withdrawal from the market in 2014 and 2015. It was reintroduced at a high price in 2016, after which use remained low.
Meanwhile, investigators found that the use of ivermectin, which is less expensive but is not considered effective against hookworm, increased over time.
Data was abstracted from IBM MarketScan Research Databases for patients with private insurance from 2010 to 2018. Standard-of-care (SOC) drugs for hookworm and pinworm include albendazole, mebendazole, and over-the-counter pyrantel pamoate.
Hookworm is a tropical disease that affects about 576 million to 740 million people worldwide, according to the CDC.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More
